Maze Therapeutics jumps on early data for kidney disease drug

Maze Therapeutics

11/09/2025 12:52

** Shares of drug developer Maze Therapeutics MAZE.O rise 35% to $21.77 premarket

** Company says its experimental oral drug, MZE782, showed strong results in an early-stage trial

** The drug, which blocks a protein called SLC6A19, led to a sharp increase in the amounts of phenylalanine and glutamine excreted in urine

** Company says it plans to begin mid-stage studies in 2026 for phenylketonuria, a rare genetic disorder, and chronic kidney disease, a long-term condition affecting kidney function

** No serious side-effects were reported in the study, which tested the drug in 112 healthy adults, company says

** As of last close, stock up 0.4% YTD

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))